This is a list of all content pages that are marked reviewed, but after the review it was subsequently edited. Presumably these pages need to be reviewed again.
11257 reviews are up to date. 1454 reviews are stale and are listed below.
- Toward defining the autoimmune microbiome for type 1 diabetes
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 1
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 1/Signature 1
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 1/Signature 2
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 2
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 2/Signature 1
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 2/Signature 2
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 3
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 3/Signature 1
- Toward defining the autoimmune microbiome for type 1 diabetes/Experiment 3/Signature 2
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without/Experiment 1
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without/Experiment 1/Signature 1
- Fecal microbiota composition differs between children with β-cell autoimmunity and those without/Experiment 1/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 1/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 1/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 2/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 2/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 3
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 3/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 3/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 4
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 4/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 4/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 5
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 5/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 5/Signature 2
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 6
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 6/Signature 1
- Human gut microbiota changes reveal the progression of glucose intolerance/Experiment 6/Signature 2
- Effect of metformin on metabolic improvement and gut microbiota
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 1/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 2
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 2/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 3
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 3/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 4
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 4/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 4/Signature 2
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 5
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 5/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 5/Signature 2
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 6
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 6/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 6/Signature 2
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 7
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 7/Signature 1
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 8
- Effect of metformin on metabolic improvement and gut microbiota/Experiment 8/Signature 1
- Structural changes in the gut microbiome of constipated patients
- Structural changes in the gut microbiome of constipated patients/Experiment 1
- Structural changes in the gut microbiome of constipated patients/Experiment 1/Signature 1
- Structural changes in the gut microbiome of constipated patients/Experiment 1/Signature 2
- Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes
- Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes/Experiment 1
- Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes/Experiment 1/Signature 1
- Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes/Experiment 1/Signature 2
- Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes
- Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes/Experiment 1
- Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes/Experiment 1/Signature 1
- Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes/Experiment 1/Signature 2
- Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes/Experiment 2
- Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes/Experiment 2/Signature 1
- Antibiotics in early life alter the gut microbiome and increase disease incidence in a spontaneous mouse model of autoimmune insulin-dependent diabetes/Experiment 2/Signature 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 1/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 2/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 2/Signature 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 3
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 3/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 3/Signature 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 4
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 4/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 4/Signature 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 5
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 5/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 5/Signature 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 6
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 6/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 6/Signature 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 7
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 7/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 7/Signature 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 8
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 8/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 8/Signature 2
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 9
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 9/Signature 1
- Alterations in Intestinal Microbiota Correlate With Susceptibility to Type 1 Diabetes/Experiment 9/Signature 2
- Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates
- Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates/Experiment 1
- Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates/Experiment 1/Signature 2
- Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates/Experiment 2
- Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates/Experiment 2/Signature 1
- Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates/Experiment 2/Signature 2
- Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses
- Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses/Experiment 1
- Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses/Experiment 1/Signature 1
- Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses/Experiment 1/Signature 2
- Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses/Experiment 2
- Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses/Experiment 2/Signature 1
- Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses/Experiment 2/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 1/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 1/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 2/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 2/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 3
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 3/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 3/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 4
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 4/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 4/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 5
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 5/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 5/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 6
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 6/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 6/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 7
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 7/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 7/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 8
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 8/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 8/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 9
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 9/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 9/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 10
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 10/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 10/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 11
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 11/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 11/Signature 2
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 12
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 12/Signature 1
- A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial/Experiment 12/Signature 2
- Microbial Diversity of Genital Ulcers of HSV-2 Seropositive Women
- Microbial Diversity of Genital Ulcers of HSV-2 Seropositive Women/Experiment 1
- Microbial Diversity of Genital Ulcers of HSV-2 Seropositive Women/Experiment 1/Signature 1
- Microbial Diversity of Genital Ulcers of HSV-2 Seropositive Women/Experiment 2
- Microbial Diversity of Genital Ulcers of HSV-2 Seropositive Women/Experiment 2/Signature 2
- Comparison of DNA extraction methods for human gut microbial community profiling
- Comparison of DNA extraction methods for human gut microbial community profiling/Experiment 1
- Comparison of DNA extraction methods for human gut microbial community profiling/Experiment 1/Signature 1
- Comparison of DNA extraction methods for human gut microbial community profiling/Experiment 1/Signature 2
- Comparison of DNA extraction methods for human gut microbial community profiling/Experiment 2
- Comparison of DNA extraction methods for human gut microbial community profiling/Experiment 2/Signature 1
- Comparison of DNA extraction methods for human gut microbial community profiling/Experiment 2/Signature 2
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 1
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 1/Signature 1
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 2
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 2/Signature 1
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 3
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 3/Signature 1
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 4
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 4/Signature 1
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 4/Signature 2
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 5
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 5/Signature 1
- Zengye decoction induces alterations to metabolically active gut microbiota in aged constipated rats/Experiment 5/Signature 2
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 1
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 1/Signature 1
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 1/Signature 2
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 2
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 2/Signature 1
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 2/Signature 2
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 3
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 3/Signature 1
- The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls/Experiment 3/Signature 2
- The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1
- The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 1
- The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy/Experiment 1/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 1/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 2/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 3/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 4/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 5/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 6/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 7/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 8/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 9
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 9/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 10/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 11/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 12/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 13
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 14
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 15
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 15/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 16/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 17
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 18
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 19/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20/Signature 1
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 20/Signature 2
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 21
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 22
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 23
- Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models/Experiment 23/Signature 1
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 1
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 2
- Cigarette smoking and oral microbiota in low-income and African-American populations/Experiment 3
- The composition of intestinal microbiota and its association with functional constipation of the elderly patients
- The composition of intestinal microbiota and its association with functional constipation of the elderly patients/Experiment 1
- The composition of intestinal microbiota and its association with functional constipation of the elderly patients/Experiment 1/Signature 1
- The composition of intestinal microbiota and its association with functional constipation of the elderly patients/Experiment 1/Signature 2
- The composition of intestinal microbiota and its association with functional constipation of the elderly patients/Experiment 2
- The composition of intestinal microbiota and its association with functional constipation of the elderly patients/Experiment 2/Signature 1
- The composition of intestinal microbiota and its association with functional constipation of the elderly patients/Experiment 2/Signature 2
- Comparison of vaginal microbiota in gynecologic cancer patients pre- and post-radiation therapy and healthy women
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 1
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 1/Signature 1
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 1/Signature 2
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 2
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 2/Signature 1
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 2/Signature 2
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 3
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 3/Signature 1
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 3/Signature 2
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 4
- Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel/Experiment 4/Signature 1
- Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease
- Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease/Experiment 1
- Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease/Experiment 1/Signature 1
- Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease/Experiment 1/Signature 2
- Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease/Experiment 2
- Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease/Experiment 2/Signature 1
- Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease/Experiment 2/Signature 2
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 1
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 1/Signature 1
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 1/Signature 2
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 2
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 3
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 3/Signature 1
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 3/Signature 2
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 4
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 4/Signature 1
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 4/Signature 2
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 5
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 5/Signature 1
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 6
- Blue poo: impact of gut transit time on the gut microbiome using a novel marker/Experiment 6/Signature 1
- Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing
- Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing/Experiment 1
- Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing/Experiment 1/Signature 1
- Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing/Experiment 2
- Deciphering Gut Microbiota Dysbiosis and Corresponding Genetic and Metabolic Dysregulation in Psoriasis Patients Using Metagenomics Sequencing/Experiment 2/Signature 1
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 1
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 1/Signature 1
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 1/Signature 2
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 2
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 2/Signature 1
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 2/Signature 2
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 4
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 4/Signature 1
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 5
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 5/Signature 1
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 5/Signature 2
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 6
- Impact of sugar beet pulp and wheat bran on serum biochemical profile, inflammatory responses and gut microbiota in sows during late gestation and lactation/Experiment 6/Signature 1
- Mucosa-associated gut microbiome in Japanese patients with functional constipation
- Mucosa-associated gut microbiome in Japanese patients with functional constipation/Experiment 1
- Mucosa-associated gut microbiome in Japanese patients with functional constipation/Experiment 1/Signature 1
- Mucosa-associated gut microbiome in Japanese patients with functional constipation/Experiment 2
- Mucosa-associated gut microbiome in Japanese patients with functional constipation/Experiment 2/Signature 1
- Mucosa-associated gut microbiome in Japanese patients with functional constipation/Experiment 2/Signature 2
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 1/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 2
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 2/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 3
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 3/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 4
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 4/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 5
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 5/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 5/Signature 2
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 6
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 6/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 6/Signature 2
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 7
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 7/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 7/Signature 2
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 8
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 8/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 8/Signature 2
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 9
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 9/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 9/Signature 2
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 10
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 10/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 11
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 11/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 11/Signature 2
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 12
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 12/Signature 1
- Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice/Experiment 12/Signature 2
- Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease
- Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease/Experiment 1
- Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease/Experiment 1/Signature 1
- Predicting the Role of the Human Gut Microbiome in Constipation Using Machine-Learning Methods: A Meta-Analysis
- Predicting the Role of the Human Gut Microbiome in Constipation Using Machine-Learning Methods: A Meta-Analysis/Experiment 1
- Predicting the Role of the Human Gut Microbiome in Constipation Using Machine-Learning Methods: A Meta-Analysis/Experiment 1/Signature 1
- Predicting the Role of the Human Gut Microbiome in Constipation Using Machine-Learning Methods: A Meta-Analysis/Experiment 1/Signature 2
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 1
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 1/Signature 1
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 1/Signature 2
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 2
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 2/Signature 1
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 2/Signature 2
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 3
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 3/Signature 1
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 4
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 4/Signature 1
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 5
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 5/Signature 1
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 6
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 6/Signature 1
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 7
- Characteristics of the Intestinal Microorganisms in Middle-Aged and Elderly Patients: Effects of Smoking/Experiment 7/Signature 1
- Gut Metagenome as a Potential Diagnostic and Predictive Biomarker in Slow Transit Constipation
- Gut Metagenome as a Potential Diagnostic and Predictive Biomarker in Slow Transit Constipation/Experiment 1
- Gut Metagenome as a Potential Diagnostic and Predictive Biomarker in Slow Transit Constipation/Experiment 1/Signature 1
- Gut Metagenome as a Potential Diagnostic and Predictive Biomarker in Slow Transit Constipation/Experiment 1/Signature 2
- High-Fat Diet Enhances the Liver Metastasis Potential of Colorectal Cancer through Microbiota Dysbiosis
- High-Fat Diet Enhances the Liver Metastasis Potential of Colorectal Cancer through Microbiota Dysbiosis/Experiment 1
- High-Fat Diet Enhances the Liver Metastasis Potential of Colorectal Cancer through Microbiota Dysbiosis/Experiment 1/Signature 1
- High-Fat Diet Enhances the Liver Metastasis Potential of Colorectal Cancer through Microbiota Dysbiosis/Experiment 1/Signature 2
- High-Fat Diet Enhances the Liver Metastasis Potential of Colorectal Cancer through Microbiota Dysbiosis/Experiment 2
- High-Fat Diet Enhances the Liver Metastasis Potential of Colorectal Cancer through Microbiota Dysbiosis/Experiment 2/Signature 1
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease/Experiment 1
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease/Experiment 1/Signature 1
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease/Experiment 2
- Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease/Experiment 2/Signature 1
- Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance
- Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance/Experiment 1
- Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance/Experiment 1/Signature 1
- Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance/Experiment 1/Signature 2
- Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance/Experiment 2
- Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance/Experiment 2/Signature 1
- Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance/Experiment 2/Signature 2
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 1
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 1/Signature 1
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 4
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 4/Signature 1
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 4/Signature 2
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 5
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 5/Signature 1
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 5/Signature 2
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 6
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 6/Signature 1
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 6/Signature 2
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 7
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 7/Signature 1
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 7/Signature 2
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 8
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 8/Signature 1
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 8/Signature 2
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 9
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 9/Signature 1
- Alleviating effects of gut micro-ecologically regulatory treatments on mice with constipation/Experiment 9/Signature 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 1
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 1/Signature 1
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 1/Signature 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 2/Signature 1
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 2/Signature 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 3
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 3/Signature 1
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 3/Signature 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 4
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 4/Signature 1
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 4/Signature 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 5
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 5/Signature 1
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 5/Signature 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 6
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 6/Signature 1
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 6/Signature 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 7
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 7/Signature 1
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 7/Signature 2
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 8
- The human gut microbiota and glucose metabolism: a scoping review of key bacteria and the potential role of SCFAs/Experiment 8/Signature 1
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer/Experiment 1
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer/Experiment 1/Signature 1
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer/Experiment 1/Signature 2
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer/Experiment 2
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer/Experiment 2/Signature 1
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer/Experiment 2/Signature 2
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer/Experiment 3
- Gut microbiota composition in chemotherapy and targeted therapy of patients with metastatic colorectal cancer/Experiment 3/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 1/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 1/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 2/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 2/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 3
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 3/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 3/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 4
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 4/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 4/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 5
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 5/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 5/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 6
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 6/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 7
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 7/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 8
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 8/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 9
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 9/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 9/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 10
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 10/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 10/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 11
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 11/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 11/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 12
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 12/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 12/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 13
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 13/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 13/Signature 2
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 14
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 14/Signature 1
- Altered gut microbiome composition in nontreated plaque psoriasis patients/Experiment 14/Signature 2
- The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy
- The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy/Experiment 1
- The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy/Experiment 1/Signature 1
- The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy/Experiment 1/Signature 2
- The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy/Experiment 2
- The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy/Experiment 2/Signature 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 1/Signature 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 1/Signature 2
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 2
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 2/Signature 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 2/Signature 2
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 3
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 3/Signature 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 3/Signature 2
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 4
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 4/Signature 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 4/Signature 2
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 5
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 5/Signature 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 6
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 6/Signature 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 6/Signature 2
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 7
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 7/Signature 1
- Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle factors, and psychological status/Experiment 7/Signature 2
- Association of aberrant brain network dynamics with gut microbial composition uncovers disrupted brain-gut-microbiome interactions in irritable bowel syndrome: Preliminary findings
- Association of aberrant brain network dynamics with gut microbial composition uncovers disrupted brain-gut-microbiome interactions in irritable bowel syndrome: Preliminary findings/Experiment 1
- Association of aberrant brain network dynamics with gut microbial composition uncovers disrupted brain-gut-microbiome interactions in irritable bowel syndrome: Preliminary findings/Experiment 1/Signature 1
- Association of aberrant brain network dynamics with gut microbial composition uncovers disrupted brain-gut-microbiome interactions in irritable bowel syndrome: Preliminary findings/Experiment 1/Signature 2
- The link between increased Desulfovibrio and disease severity in Parkinson's disease
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 1
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 1/Signature 1
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 1/Signature 2
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 2
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 2/Signature 1
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 3
- The link between increased Desulfovibrio and disease severity in Parkinson's disease/Experiment 3/Signature 1
- Characteristics of the Gut Microbiome and Serum Metabolome in Patients with Functional Constipation
- Characteristics of the Gut Microbiome and Serum Metabolome in Patients with Functional Constipation/Experiment 1
- Characteristics of the Gut Microbiome and Serum Metabolome in Patients with Functional Constipation/Experiment 1/Signature 1
- Characteristics of the Gut Microbiome and Serum Metabolome in Patients with Functional Constipation/Experiment 1/Signature 2
- Characteristics of the Gut Microbiome and Serum Metabolome in Patients with Functional Constipation/Experiment 2
- Characteristics of the Gut Microbiome and Serum Metabolome in Patients with Functional Constipation/Experiment 2/Signature 1
- Characteristics of the Gut Microbiome and Serum Metabolome in Patients with Functional Constipation/Experiment 2/Signature 2
- Differences in gut microbiota and its metabolic function among different fasting plasma glucose groups in Mongolian population of China
- Differences in gut microbiota and its metabolic function among different fasting plasma glucose groups in Mongolian population of China/Experiment 1
- Differences in gut microbiota and its metabolic function among different fasting plasma glucose groups in Mongolian population of China/Experiment 1/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 1/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 1/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 2/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 2/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 3
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 3/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 3/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 4
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 4/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 4/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 5
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 5/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 5/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 6
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 6/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 6/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 7
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 7/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 7/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 8
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 8/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 8/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 9
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 9/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 9/Signature 2
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 10
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 10/Signature 1
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 11
- Reducing bias in microbiome research: Comparing methods from sample collection to sequencing/Experiment 11/Signature 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 1/Signature 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 2
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 2/Signature 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 3
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 3/Signature 1
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 4
- Differences in the gut microbiome across typical ageing and in Parkinson's disease/Experiment 4/Signature 1
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 1
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 1/Signature 1
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 1/Signature 2
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 2
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 2/Signature 1
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 2/Signature 2
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 3
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 3/Signature 1
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 3/Signature 2
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 4
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 4/Signature 1
- Fecal Microbiota Composition, Their Interactions, and Metagenome Function in US Adults with Type 2 Diabetes According to Enterotypes/Experiment 4/Signature 2
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 1
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 1/Signature 1
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 1/Signature 2
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 3
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 3/Signature 1
- Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes/Experiment 3/Signature 2
- Ischaemic stroke patients present sex differences in gut microbiota
- Ischaemic stroke patients present sex differences in gut microbiota/Experiment 1
- Ischaemic stroke patients present sex differences in gut microbiota/Experiment 1/Signature 1
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 1
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 1/Signature 1
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 1/Signature 2
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 2
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 2/Signature 1
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 2/Signature 2
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 3
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 3/Signature 1
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 3/Signature 2
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 4
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 4/Signature 1
- Oral and gut microbial biomarkers of susceptibility to respiratory tract infection in adults: A feasibility study/Experiment 4/Signature 2
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 1
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 1/Signature 1
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 2
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 2/Signature 1
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 3
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 3/Signature 1
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 4
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 4/Signature 1
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 4/Signature 2
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 5
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 5/Signature 1
- Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites/Experiment 5/Signature 2
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 1
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 1/Signature 1
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 1/Signature 2
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 2
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 2/Signature 1
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 2/Signature 2
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 3
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 3/Signature 1
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 3/Signature 2
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 4
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 4/Signature 1
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 4/Signature 2
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 5
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 5/Signature 1
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 5/Signature 3
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 6
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 6/Signature 1
- Unveiling the microbiome during post-partum uterine infection: a deep shotgun sequencing approach to characterize the dairy cow uterine microbiome/Experiment 6/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 1/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 1/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 2/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 2/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 3
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 3/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 3/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 4
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 4/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 4/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 5
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 5/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 5/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 6
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 6/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 6/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 7
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 7/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 7/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 8
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 8/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 8/Signature 2
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 9
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 9/Signature 1
- The gut microbiome and metabolites are altered and interrelated in patients with functional constipation/Experiment 9/Signature 2
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 1
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 1/Signature 1
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 1/Signature 2
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 2
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 2/Signature 1
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 2/Signature 2
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 3
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 3/Signature 1
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 4
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 4/Signature 1
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 5
- Orally administered neohesperidin attenuates MPTP-induced neurodegeneration by inhibiting inflammatory responses and regulating intestinal flora in mice/Experiment 5/Signature 1
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 1
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 1/Signature 1
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 1/Signature 2
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 2
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 2/Signature 1
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 2/Signature 2
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 3
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 3/Signature 1
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 4
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 4/Signature 1
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 4/Signature 2
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 5
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 5/Signature 1
- Altered gut microbial profile is associated with differentially expressed fecal microRNAs in patients with functional constipation/Experiment 5/Signature 2
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 1
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 1/Signature 1
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 1/Signature 2
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 2
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 2/Signature 1
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 2/Signature 2
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 3
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 3/Signature 1
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 3/Signature 2
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 4
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 4/Signature 1
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 5
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 5/Signature 1
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 5/Signature 2
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 6
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 6/Signature 1
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 6/Signature 2
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 7
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 7/Signature 1
- Characteristics of Oral-Gut Microbiota in Model Rats with CUMS-Induced Depression/Experiment 7/Signature 2
- Melatonin alleviates high temperature exposure induced fetal growth restriction via the gut-placenta-fetus axis in pregnant mice
- Melatonin alleviates high temperature exposure induced fetal growth restriction via the gut-placenta-fetus axis in pregnant mice/Experiment 1
- Melatonin alleviates high temperature exposure induced fetal growth restriction via the gut-placenta-fetus axis in pregnant mice/Experiment 1/Signature 1
- Melatonin alleviates high temperature exposure induced fetal growth restriction via the gut-placenta-fetus axis in pregnant mice/Experiment 2
- Melatonin alleviates high temperature exposure induced fetal growth restriction via the gut-placenta-fetus axis in pregnant mice/Experiment 2/Signature 1
- Melatonin alleviates high temperature exposure induced fetal growth restriction via the gut-placenta-fetus axis in pregnant mice/Experiment 3
- Melatonin alleviates high temperature exposure induced fetal growth restriction via the gut-placenta-fetus axis in pregnant mice/Experiment 3/Signature 1
- Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance
- Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance/Experiment 1
- Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance/Experiment 1/Signature 1
- Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance/Experiment 1/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 1/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 1/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 2/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 2/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 3
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 3/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 3/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 4
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 4/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 4/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 5
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 5/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 5/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 6
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 6/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 6/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 7
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 7/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 7/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 8
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 8/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 8/Signature 2
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 9
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 9/Signature 1
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 10
- Gastrointestinal Dysmotility Predisposes to Colitis through Regulation of Gut Microbial Composition and Linoleic Acid Metabolism/Experiment 10/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 1/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 1/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 2/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 2/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 3
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 3/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 3/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 4
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 4/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 4/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 5
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 5/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 5/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 6
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 6/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 6/Signature 2
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 7
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 7/Signature 1
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 8
- Large-scale causal analysis of gut microbiota and six common complications of diabetes: a mendelian randomization study/Experiment 8/Signature 1
- Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma/Experiment 1
- Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma/Experiment 2
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development/Experiment 1
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development/Experiment 1/Signature 1
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development/Experiment 2
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development/Experiment 2/Signature 1
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development/Experiment 3
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development/Experiment 3/Signature 1
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development/Experiment 5
- Microbiome confounders and quantitative profiling challenge predicted microbial targets in colorectal cancer development/Experiment 5/Signature 1
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 1
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 1/Signature 1
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 1/Signature 4
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 3
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 3/Signature 1
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 3/Signature 2
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 4
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 4/Signature 1
- The Role of Gut Microbiota in Male Erectile Dysfunction of Rats/Experiment 4/Signature 2
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 1
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 1/Signature 1
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 1/Signature 2
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 2
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 2/Signature 1
- Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease/Experiment 2/Signature 2
- Altitude-dependent agro-ecologies impact the microbiome diversity of scavenging indigenous chicken in Ethiopia
- Altitude-dependent agro-ecologies impact the microbiome diversity of scavenging indigenous chicken in Ethiopia/Experiment 1
- Altitude-dependent agro-ecologies impact the microbiome diversity of scavenging indigenous chicken in Ethiopia/Experiment 1/Signature 1
- Altitude-dependent agro-ecologies impact the microbiome diversity of scavenging indigenous chicken in Ethiopia/Experiment 2
- Altitude-dependent agro-ecologies impact the microbiome diversity of scavenging indigenous chicken in Ethiopia/Experiment 2/Signature 2
- Altitude-dependent agro-ecologies impact the microbiome diversity of scavenging indigenous chicken in Ethiopia/Experiment 3
- Altitude-dependent agro-ecologies impact the microbiome diversity of scavenging indigenous chicken in Ethiopia/Experiment 3/Signature 1
- Metagenome-assembled microbial genomes from Parkinson's disease fecal samples
- Metagenome-assembled microbial genomes from Parkinson's disease fecal samples/Experiment 1
- Metagenome-assembled microbial genomes from Parkinson's disease fecal samples/Experiment 1/Signature 1
- Metagenome-assembled microbial genomes from Parkinson's disease fecal samples/Experiment 1/Signature 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 1/Signature 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 1/Signature 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 2/Signature 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 2/Signature 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 3
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 3/Signature 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 3/Signature 2
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 4
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 4/Signature 1
- Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease/Experiment 4/Signature 2
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 1
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 1/Signature 1
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 1/Signature 2
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 2
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 2/Signature 1
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 2/Signature 2
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 3
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 3/Signature 1
- The impact of small intestinal bacterial overgrowth on the efficacy of fecal microbiota transplantation in patients with chronic constipation/Experiment 3/Signature 2
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 1
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 1/Signature 1
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 1/Signature 2
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 2
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 2/Signature 1
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 2/Signature 2
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 3
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 3/Signature 1
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 3/Signature 2
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 5
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 5/Signature 1
- Integrated analysis of microbiome and metabolome reveals signatures in PDAC tumorigenesis and prognosis/Experiment 5/Signature 2
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 1
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 1/Signature 1
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 1/Signature 2
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 2
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 2/Signature 1
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 2/Signature 2
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 3
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 3/Signature 1
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 6
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 6/Signature 1
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 6/Signature 2
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 7
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 7/Signature 1
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 7/Signature 2
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 8
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 8/Signature 1
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 9
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 9/Signature 1
- Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT/Experiment 9/Signature 2
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan/Experiment 1
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan/Experiment 1/Signature 1
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan/Experiment 1/Signature 2
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan/Experiment 2
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan/Experiment 2/Signature 1
- Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan/Experiment 2/Signature 2
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 1
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 1/Signature 1
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 1/Signature 2
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 2
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 2/Signature 1
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 2/Signature 2
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 3
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 3/Signature 1
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 3/Signature 2
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 4
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 4/Signature 1
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 4/Signature 2
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 5
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 5/Signature 1
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 5/Signature 2
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 6
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 6/Signature 1
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 6/Signature 2
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 7
- The respiratory microbiome is linked to the severity of RSV infections and the persistence of symptoms in children/Experiment 7/Signature 1
- Gut dysbiosis narrative in psoriasis: matched-pair approach identifies only subtle shifts correlated with elevated fecal calprotectin
- Gut dysbiosis narrative in psoriasis: matched-pair approach identifies only subtle shifts correlated with elevated fecal calprotectin/Experiment 1
- Gut dysbiosis narrative in psoriasis: matched-pair approach identifies only subtle shifts correlated with elevated fecal calprotectin/Experiment 1/Signature 1
- Gut dysbiosis narrative in psoriasis: matched-pair approach identifies only subtle shifts correlated with elevated fecal calprotectin/Experiment 1/Signature 2
- Gut dysbiosis narrative in psoriasis: matched-pair approach identifies only subtle shifts correlated with elevated fecal calprotectin/Experiment 2
- Gut dysbiosis narrative in psoriasis: matched-pair approach identifies only subtle shifts correlated with elevated fecal calprotectin/Experiment 2/Signature 1
- Gut dysbiosis narrative in psoriasis: matched-pair approach identifies only subtle shifts correlated with elevated fecal calprotectin/Experiment 2/Signature 2
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 1
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 1/Signature 1
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 1/Signature 2
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 2
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 2/Signature 1
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 2/Signature 2
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 3
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 3/Signature 1
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 3/Signature 2
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 4
- The regulatory effect of chitooligosaccharides on islet inflammation in T2D individuals after islet cell transplantation: the mechanism behind Candida albicans abundance and macrophage polarization/Experiment 4/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 1/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 2
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 2/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 3
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 3/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 4
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 4/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 5
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 5/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 6
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 6/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 7
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 7/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 8
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 8/Signature 1
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 9
- New insights into the combined effects of aflatoxin B1 and Eimeria ovinoidalis on uterine function by disrupting the gut-blood-reproductive axis in sheep/Experiment 9/Signature 1
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 1
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 1/Signature 1
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 1/Signature 2
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 2
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 2/Signature 1
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 2/Signature 2
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 3
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 3/Signature 1
- Modulating the human gut microbiome and health markers through kombucha consumption: a controlled clinical study/Experiment 3/Signature 2
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people/Experiment 1
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people/Experiment 1/Signature 1
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people/Experiment 2
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people/Experiment 2/Signature 1
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people/Experiment 3
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people/Experiment 3/Signature 1
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people/Experiment 4
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people/Experiment 4/Signature 1
- Interconnected pathways link faecal microbiota plasma lipids and brain activity to childhood malnutrition related cognition
- Interconnected pathways link faecal microbiota plasma lipids and brain activity to childhood malnutrition related cognition/Experiment 1
- Interconnected pathways link faecal microbiota plasma lipids and brain activity to childhood malnutrition related cognition/Experiment 1/Signature 1
- Interconnected pathways link faecal microbiota plasma lipids and brain activity to childhood malnutrition related cognition/Experiment 1/Signature 2
- The gut microbiota-SCFA-inflammation axis in patients with AECOPD
- The gut microbiota-SCFA-inflammation axis in patients with AECOPD/Experiment 1
- The gut microbiota-SCFA-inflammation axis in patients with AECOPD/Experiment 1/Signature 1
- The gut microbiota-SCFA-inflammation axis in patients with AECOPD/Experiment 1/Signature 2
- The gut microbiota-SCFA-inflammation axis in patients with AECOPD/Experiment 2
- The gut microbiota-SCFA-inflammation axis in patients with AECOPD/Experiment 2/Signature 1
- The gut microbiota-SCFA-inflammation axis in patients with AECOPD/Experiment 2/Signature 2
- Appearance of green tea compounds in plasma following acute green tea consumption is modulated by the gut microbiome in mice
- Appearance of green tea compounds in plasma following acute green tea consumption is modulated by the gut microbiome in mice/Experiment 1
- Appearance of green tea compounds in plasma following acute green tea consumption is modulated by the gut microbiome in mice/Experiment 1/Signature 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 1/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 2/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 2/Signature 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 3
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 3/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 3/Signature 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 4
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 4/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 4/Signature 2
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 5
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 5/Signature 1
- Fecal Microbiota Transplantation (FMT) From a Human at Low Risk for Alzheimer's Disease Improves Short-Term Recognition Memory and Increases Neuroinflammation in a 3xTg AD Mouse Model/Experiment 5/Signature 2
- Altered microbiome and metabolome profiling in fearful companion dogs: An exploratory study
- Altered microbiome and metabolome profiling in fearful companion dogs: An exploratory study/Experiment 1
- Altered microbiome and metabolome profiling in fearful companion dogs: An exploratory study/Experiment 1/Signature 1
- Altered microbiome and metabolome profiling in fearful companion dogs: An exploratory study/Experiment 1/Signature 2
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 1
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 1/Signature 1
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 1/Signature 2
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 2
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 2/Signature 1
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 3
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 3/Signature 1
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 4
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 4/Signature 1
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 5
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 5/Signature 1
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 6
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 6/Signature 1
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 7
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 7/Signature 1
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 8
- Gut microbial dysbiosis, IgA, and Enterococcus in common variable immunodeficiency with immune dysregulation/Experiment 8/Signature 1
- Characteristics of functional constipation and analysis of intestinal microbiota in children aged 0-4 in Zunyi region
- Characteristics of functional constipation and analysis of intestinal microbiota in children aged 0-4 in Zunyi region/Experiment 1
- Characteristics of functional constipation and analysis of intestinal microbiota in children aged 0-4 in Zunyi region/Experiment 1/Signature 1
- Characteristics of functional constipation and analysis of intestinal microbiota in children aged 0-4 in Zunyi region/Experiment 1/Signature 3
- Characteristics of functional constipation and analysis of intestinal microbiota in children aged 0-4 in Zunyi region/Experiment 2
- Characteristics of functional constipation and analysis of intestinal microbiota in children aged 0-4 in Zunyi region/Experiment 2/Signature 1
- Characteristics of functional constipation and analysis of intestinal microbiota in children aged 0-4 in Zunyi region/Experiment 2/Signature 2
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study/Experiment 1
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study/Experiment 1/Signature 1
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study/Experiment 2
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study/Experiment 2/Signature 1
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study/Experiment 3
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study/Experiment 3/Signature 1
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study/Experiment 3/Signature 2
- Dysbiosis of infant gut microbiota is related to the altered fatty acid composition of human milk from mothers with gestational diabetes mellitus: a prospective cohort study/Experiment 4/Signature 1
- Microbiome analysis in individuals with human papillomavirus oral infection
- Microbiome analysis in individuals with human papillomavirus oral infection/Experiment 1
- Microbiome analysis in individuals with human papillomavirus oral infection/Experiment 1/Signature 1
- Microbiome analysis in individuals with human papillomavirus oral infection/Experiment 1/Signature 2
- Microbiome analysis in individuals with human papillomavirus oral infection/Experiment 2
- Microbiome analysis in individuals with human papillomavirus oral infection/Experiment 2/Signature 1
- Microbiome analysis in individuals with human papillomavirus oral infection/Experiment 2/Signature 2
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 1/Signature 2
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 1/Signature 3
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 3
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 3/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 3/Signature 2
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 4
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 4/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 5
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 5/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 5/Signature 2
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 6
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 6/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 7
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 7/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 8
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 8/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 8/Signature 2
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 9
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 9/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 10
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 10/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 11
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 11/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 11/Signature 2
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 12
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 12/Signature 1
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 13
- Associations between the gut microbiome, inflammation and cardiovascular profiles in people with HIV/Experiment 13/Signature 1
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder/Experiment 6
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder/Experiment 6/Signature 1
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder/Experiment 6/Signature 2
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder/Experiment 7
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder/Experiment 7/Signature 1
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder/Experiment 7/Signature 2
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder/Experiment 8
- Impact of psychostimulants on microbiota and short-chain fatty acids alterations in children with attention-deficit/hyperactivity disorder/Experiment 8/Signature 1
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 1
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 1/Signature 1
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 1/Signature 2
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 2
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 2/Signature 1
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 2/Signature 2
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 3
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 3/Signature 1
- No rumen fermentation profiles and associated microbial diversities difference were found between Hu sheep and Karakul sheep fed a cottonseed hull diet/Experiment 3/Signature 2
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 1/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 2
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 2/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 3
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 3/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 4
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 4/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 4/Signature 2
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 5
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 5/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 5/Signature 2
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 6
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 6/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 6/Signature 2
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 7
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 7/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 8
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 8/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 9
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 9/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 10
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 10/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 11
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 11/Signature 1
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 12
- Effects of vaginal microbiota on in vitro fertilization outcomes in women with different infertility causes/Experiment 12/Signature 1
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study/Experiment 1
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study/Experiment 1/Signature 1
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study/Experiment 2
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study/Experiment 2/Signature 1
- Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study/Experiment 2/Signature 2
- Personalized prediction of glycemic responses to food in women with diet-treated gestational diabetes: the role of the gut microbiota
- Personalized prediction of glycemic responses to food in women with diet-treated gestational diabetes: the role of the gut microbiota/Experiment 1
- Personalized prediction of glycemic responses to food in women with diet-treated gestational diabetes: the role of the gut microbiota/Experiment 1/Signature 1
- Personalized prediction of glycemic responses to food in women with diet-treated gestational diabetes: the role of the gut microbiota/Experiment 1/Signature 2
- Personalized prediction of glycemic responses to food in women with diet-treated gestational diabetes: the role of the gut microbiota/Experiment 2
- Personalized prediction of glycemic responses to food in women with diet-treated gestational diabetes: the role of the gut microbiota/Experiment 2/Signature 1
- Personalized prediction of glycemic responses to food in women with diet-treated gestational diabetes: the role of the gut microbiota/Experiment 2/Signature 2
- Fecal microbiota transplantation modulates jejunal host-microbiota interface in weanling piglets
- Fecal microbiota transplantation modulates jejunal host-microbiota interface in weanling piglets/Experiment 2
- Fecal microbiota transplantation modulates jejunal host-microbiota interface in weanling piglets/Experiment 2/Signature 1
- Fecal microbiota transplantation modulates jejunal host-microbiota interface in weanling piglets/Experiment 2/Signature 2
- Fecal microbiota transplantation modulates jejunal host-microbiota interface in weanling piglets/Experiment 3
- Fecal microbiota transplantation modulates jejunal host-microbiota interface in weanling piglets/Experiment 3/Signature 1
- Fecal microbiota transplantation modulates jejunal host-microbiota interface in weanling piglets/Experiment 3/Signature 2
- A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma
- A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma/Experiment 1
- A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma/Experiment 1/Signature 1
- A gut-on-a-chip incorporating human faecal samples and peristalsis predicts responses to immune checkpoint inhibitors for melanoma/Experiment 1/Signature 2
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 1/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 2
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 2/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 2/Signature 2
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 3
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 3/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 4
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 4/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 5
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 5/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 5/Signature 2
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 6
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 6/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 7
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 7/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 8
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 8/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 9
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 9/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 10
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 10/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 11
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 11/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 12
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 12/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 13
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 13/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 14
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 14/Signature 1
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 15
- The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial/Experiment 15/Signature 1
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 1
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 1/Signature 1
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 1/Signature 2
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 2
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 2/Signature 1
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 2/Signature 2
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 3
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 3/Signature 1
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 3/Signature 2
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 4
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 4/Signature 1
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 4/Signature 2
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 5
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 5/Signature 1
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 5/Signature 2
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 6
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 6/Signature 1
- Probiotic supplementation mitigates sex-dependent nociceptive changes and gut dysbiosis induced by prenatal opioid exposure/Experiment 6/Signature 2
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 1
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 1/Signature 1
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 1/Signature 2
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 2
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 2/Signature 1
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 3
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 3/Signature 1
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 3/Signature 2
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 4
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 4/Signature 1
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 5
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 5/Signature 1
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 5/Signature 2
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 6
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 6/Signature 2
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 7
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 7/Signature 1
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 7/Signature 2
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 8
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 8/Signature 1
- Gut microbiome changes with micronutrient supplementation in children with attention-deficit/hyperactivity disorder: the MADDY study/Experiment 8/Signature 2
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 1
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 1/Signature 1
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 1/Signature 2
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 2
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 2/Signature 1
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 2/Signature 2
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 3
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 3/Signature 1
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 3/Signature 2
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 4
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 4/Signature 1
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 4/Signature 2
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 5
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 5/Signature 1
- Increased dietary protein stimulates amino acid catabolism via the gut microbiota and secondary bile acid production/Experiment 5/Signature 2
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 1
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 1/Signature 1
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 1/Signature 2
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 2
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 2/Signature 1
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 2/Signature 2
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 3
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 3/Signature 1
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 3/Signature 2
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 4
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 4/Signature 1
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 4/Signature 2
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 5
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 5/Signature 1
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 5/Signature 2
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 6
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 6/Signature 1
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 6/Signature 2
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 7
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 7/Signature 1
- Gut microbial dysbiosis exacerbates long-term cognitive impairments by promoting intestinal dysfunction and neuroinflammation following neonatal hypoxia-ischemia/Experiment 7/Signature 2
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types/Experiment 1
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types/Experiment 1/Signature 1
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types/Experiment 2
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types/Experiment 2/Signature 1
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types/Experiment 2/Signature 2
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types/Experiment 3
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types/Experiment 3/Signature 1
- Exploring oral microbiome in oral squamous cell carcinoma across environment-associated sample types/Experiment 3/Signature 2
- Multi-omics analysis reveals associations between gut microbiota and host transcriptome in colon cancer patients
- Multi-omics analysis reveals associations between gut microbiota and host transcriptome in colon cancer patients/Experiment 1
- Multi-omics analysis reveals associations between gut microbiota and host transcriptome in colon cancer patients/Experiment 1/Signature 1
- Multi-omics analysis reveals associations between gut microbiota and host transcriptome in colon cancer patients/Experiment 1/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 1/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 1/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 2/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 2/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 3
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 3/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 3/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 4/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 4/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 5/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 5/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 6
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 6/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 7
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 7/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 7/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 8
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 8/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 8/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 9
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 9/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 9/Signature 2
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 10
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 10/Signature 1
- Fecal bacterial biomarkers and blood biochemical indicators as potential key factors in the development of colorectal cancer/Experiment 10/Signature 2
- Microbiome analysis of gut microbiota in patients with colorectal polyps and healthy individuals
- Microbiome analysis of gut microbiota in patients with colorectal polyps and healthy individuals/Experiment 1
- Microbiome analysis of gut microbiota in patients with colorectal polyps and healthy individuals/Experiment 1/Signature 1
- Microbiome analysis of gut microbiota in patients with colorectal polyps and healthy individuals/Experiment 1/Signature 2
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 1/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 1/Signature 2
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 2
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 2/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 2/Signature 2
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 3
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 3/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 4
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 4/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 5
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 5/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 6
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 6/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 7
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 7/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 8
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 8/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 9
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 9/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 9/Signature 2
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 10
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 10/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 11
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 11/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 11/Signature 2
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 12
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 12/Signature 1
- Therapeutic Mechanism of Zhuyang Tongbian Decoction in Treating Functional Constipation: Insights from a Pilot Study Utilizing 16S rRNA Sequencing, Metagenomics, and Metabolomics/Experiment 12/Signature 2
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 1/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 1/Signature 2
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 2
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 2/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 3
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 3/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 4
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 4/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 5
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 5/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 5/Signature 2
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 6
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 6/Signature 3
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 6/Signature 4
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 7
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 7/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 7/Signature 2
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 8
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 8/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 8/Signature 2
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 9
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 9/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 9/Signature 2
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 10
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 10/Signature 1
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 11
- Rhodococcus spp. interacts with human norovirus in clinical samples and impairs its replication on human intestinal enteroids/Experiment 11/Signature 1
- Oral microbiome diversity associates with carotid intima media thickness in middle-aged male subjects
- Oral microbiome diversity associates with carotid intima media thickness in middle-aged male subjects/Experiment 1
- Oral microbiome diversity associates with carotid intima media thickness in middle-aged male subjects/Experiment 1/Signature 1
- Oral microbiome diversity associates with carotid intima media thickness in middle-aged male subjects/Experiment 1/Signature 2
- Exploring the female genital tract mycobiome in young South African women using metaproteomics
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 1
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 1/Signature 1
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 1/Signature 2
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 2
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 2/Signature 3
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 3
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 3/Signature 1
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 4
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 4/Signature 1
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 4/Signature 2
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 5
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 5/Signature 1
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 5/Signature 2
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 8
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 8/Signature 1
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 8/Signature 2
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 9
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 9/Signature 1
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 10
- Exploring the female genital tract mycobiome in young South African women using metaproteomics/Experiment 10/Signature 1
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 1
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 1/Signature 1
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 1/Signature 2
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 2
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 2/Signature 1
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 3
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 3/Signature 1
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 3/Signature 2
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 4
- A prebiotic dietary pilot intervention restores faecal metabolites and may be neuroprotective in Parkinson's Disease/Experiment 4/Signature 1
- Associations of alcohol with the human gut microbiome and prospective health outcomes in the FINRISK 2002 cohort
- Associations of alcohol with the human gut microbiome and prospective health outcomes in the FINRISK 2002 cohort/Experiment 1
- Associations of alcohol with the human gut microbiome and prospective health outcomes in the FINRISK 2002 cohort/Experiment 1/Signature 1
- Associations of alcohol with the human gut microbiome and prospective health outcomes in the FINRISK 2002 cohort/Experiment 1/Signature 2
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 1
- Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions/Experiment 1/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 1/Signature 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 2/Signature 1
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3
- Understanding the microbial basis of body odor in pre-pubescent children and teenagers/Experiment 3/Signature 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1/Signature 1
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1/Signature 2
- Study 83
- Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters/Experiment 1
- Nasopharyngeal Microbiome Community Composition and Structure Is Associated with Severity of COVID-19 Disease and Breathing Treatment/Experiment 2
- Body site-typical microbiome signatures for adults
- Body site-typical microbiome signatures for adults/Experiment 1
- Body site-typical microbiome signatures for adults/Experiment 2
- Body site-typical microbiome signatures for adults/Experiment 3
- Body site-typical microbiome signatures for adults/Experiment 4
- Body site-typical microbiome signatures for adults/Experiment 5
- Body site-typical microbiome signatures for adults/Experiment 6
- Body site-typical microbiome signatures for adults/Experiment 7
- Body site-typical microbiome signatures for adults/Experiment 8
- Body site-typical microbiome signatures for adults/Experiment 9
- Body site-typical microbiome signatures for adults/Experiment 10
- Body site-typical microbiome signatures for adults/Experiment 10/Signature 1
- Body site-typical microbiome signatures for adults/Experiment 11
- Body site-typical microbiome signatures for children
- Body site-typical microbiome signatures for children/Experiment 1
- Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 1
- Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 2
- Investigation of systemic granulomatosis in cultured meagre, Argyrosomus regius, using clinical metagenomics/Experiment 3
- Stachyose ameliorates obesity-related metabolic syndrome via improving intestinal barrier function and remodeling gut microbiota/Experiment 1
- Gut microbiota in Parkinson’s disease patients: hospital-based study
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 1
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 1/Signature 1
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 1/Signature 2
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 2
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 2/Signature 1
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 2/Signature 2
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 3
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 3/Signature 1
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 4
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 4/Signature 1
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 6
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 6/Signature 1
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 7
- Gut microbiota in Parkinson’s disease patients: hospital-based study/Experiment 7/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 1/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 1/Signature 2
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 2
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 2/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 2/Signature 2
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 3
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 3/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 3/Signature 2
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 4
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 4/Signature 1
- Hyperglycemia is associated with duodenal dysbiosis and altered duodenal microenvironment/Experiment 4/Signature 2
